NCT03629717 2024-10-16RANKL Inhibition and Breast Tissue BiomarkersWashington University School of MedicinePhase EARLY_PHASE1 Completed10 enrolled
NCT00556374 2023-07-27Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor TherapyAmgenPhase 3 Completed3,420 enrolled 19 charts
NCT00321464 2022-11-08A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.AmgenPhase 3 Completed2,049 enrolled 16 charts
NCT02366130 2021-10-07Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast CancerM.D. Anderson Cancer CenterPhase 2 Completed45 enrolled 7 charts
NCT02900469 2020-08-21Presurgical Trial of Denosumab in Breast CancerNYU Langone HealthPhase EARLY_PHASE1 Completed44 enrolled
NCT01419717 2019-09-24Open-Label Access Protocol of Denosumab for Subjects With Advanced CancerAmgenPhase 3 Completed129 enrolled 10 charts
NCT00089661 2018-10-17AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast CancerAmgenPhase 3 Completed252 enrolled 13 charts
NCT00896454 2018-10-17Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum CalciumAmgenPhase 2 Completed33 enrolled 22 charts
NCT00950911 2014-02-11Open Label Extension to SRE Studies in United Kingdom and Czech Republic OnlyAmgenPhase 3 Completed35 enrolled 8 charts
NCT00091832 2014-01-28Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast CancerAmgenPhase 2 Completed255 enrolled 34 charts